Tourmaline Bio, Inc. (TRML)

Market Cap	402.91M
Revenue (ttm)	n/a
Net Income (ttm)	-42.12M
Shares Out	25.65M
EPS (ttm)	-8.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	303,985
Open	16.05
Previous Close	15.83
Day's Range	15.58 - 16.58
52-Week Range	9.18 - 48.31
Beta	n/a
Analysts	Strong Buy
Price Target	61.80 (+293.38%)
Earnings Date	May 15, 2024

About TRML

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2021
• Employees: 44
• Stock Exchange: NASDAQ
• Ticker Symbol: TRML

Analyst Forecast

According to 5 analysts, the average rating for TRML stock is "Strong Buy." The 12-month stock price forecast is $61.8, which is an increase of 293.38% from the latest price.

Price Target

$61.8

(293.38% upside)

Analyst Consensus: Strong Buy